Ticker > Company >

Marksans Pharma share price

Marksans Pharma Ltd.

NSE: MARKSANS BSE: 524404 SECTOR: Pharmaceuticals & Drugs  279k   1k   295

258.85
-0.30 (-0.12%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 259.95

Today's Low

₹ 249.9

52 Week High

₹ 358.5

52 Week Low

₹ 157.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

11730.14 Cr.

Enterprise Value

11417.91 Cr.

No. of Shares

45.32 Cr.

P/E

62.3

P/B

8.48

Face Value

₹ 1

Div. Yield

0.31 %

Book Value (TTM)

₹  30.53

CASH

312.23 Cr.

DEBT

0 Cr.

Promoter Holding

43.87 %

EPS (TTM)

₹  4.15

Sales Growth

30.23%

ROE

11.46 %

ROCE

14.81%

Profit Growth

30.03 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Marksans Pharma Ltd.

RelonChem Time-Caps labs Bell's Healthcare NOVA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year30.23%
3 Year12.48%
5 Year15%

Profit Growth

1 Year30.03%
3 Year10.78%
5 Year25.12%

ROE%

1 Year11.46%
3 Year12.99%
5 Year12.91%

ROCE %

1 Year14.81%
3 Year16.33%
5 Year16.77%

Debt/Equity

0

Price to Cash Flow

344.48

Interest Cover Ratio

174.9798

CFO/PAT (5 Yr. Avg.)

0.747003510191859

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 43.87 0.00
Dec 2024 43.87 0.00
Sep 2024 43.87 0.00
Jun 2024 43.87 0.00
Mar 2024 43.85 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 174.9798.
  • Company has a healthy liquidity position with current ratio of 3.216.

 Limitations

  • The company has shown a poor revenue growth of 12.4831588553793% for the Past 3 years.
  • The company is trading at a high PE of 62.3.
  • The company is trading at a high EV/EBITDA of 41.8973.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 225.2 254.53 308.63 311.87 299.36
Total Expenditure 191.29 213.26 256.35 251.93 248.78
Operating Profit 33.91 41.27 52.27 59.94 50.57
Other Income 12.19 8.15 31.36 22.51 7.82
Interest 0.23 0.28 0.28 0.3 0.31
Depreciation 7.47 6.84 7.02 7.42 8.18
Exceptional Items 0 0 0 0 0
Profit Before Tax 38.4 42.3 76.34 74.72 49.9
Tax 5.41 10.28 13.13 19.26 12.31
Profit After Tax 32.99 32.02 63.2 55.46 37.59
Adjusted EPS (Rs) 0.73 0.71 1.39 1.22 0.83

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 433.42 599.55 658.29 655.2 853.27
Total Expenditure 361.93 485.84 544.57 582.23 713.34
Operating Profit 71.49 113.71 113.72 72.97 139.94
Other Income 0.17 31.16 42.25 79.41 62.07
Interest 7.29 5.35 3.8 3.61 0.99
Depreciation 11.64 15.19 17.66 16.74 29.13
Exceptional Items 0 0 0 0 0
Profit Before Tax 52.73 124.33 134.51 132.04 171.89
Tax 14.82 25.95 30.52 29.17 38.13
Net Profit 37.9 98.38 103.99 102.87 133.76
Adjusted EPS (Rs.) 0.93 2.4 2.54 2.27 2.95

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 40.93 40.93 40.93 45.32 45.32
Total Reserves 464.69 558.79 743.74 1066.01 1177.39
Borrowings 0 0 0 0 0
Other N/C liabilities 24.79 23.94 14.41 17 20.9
Current liabilities 79.73 137.26 190.39 240.91 304.73
Total Liabilities 610.14 760.91 989.47 1369.23 1548.33
Assets
Net Block 115.18 129.09 135.51 143.94 271.58
Capital WIP 0 0 0 3.91 0
Intangible WIP 0 0 0 0 0
Investments 236.07 236.07 236.07 265.75 265.75
Loans & Advances 4.47 4.16 4.16 17.5 30.84
Other N/C Assets 0 0 0 0 0.17
Current Assets 254.41 391.6 613.73 938.13 979.99
Total Assets 610.14 760.91 989.47 1369.23 1548.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 52.73 124.33 134.51 132.04 171.89
Adjustment 19.17 -8.82 -7.93 10.91 -16.4
Changes in Assets & Liabilities 46.17 11.62 -38.77 -59.6 -82.68
Tax Paid -10.49 -20.21 -31.83 -31.62 -38.76
Operating Cash Flow 107.58 106.92 55.97 51.73 34.05
Investing Cash Flow -24.15 8.87 -128.06 -194.62 -114.22
Financing Cash Flow -81.87 -13.53 70.86 210.02 -26.22
Net Cash Flow 1.55 102.26 -1.23 67.12 -106.38

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 43.85 43.87 43.87 43.87 43.87
mark saldanha 43.80 43.80 43.80 43.80 43.80
sandra saldanha 0.05 0.07 0.07 0.07 0.07
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 56.15 56.13 56.13 56.13 56.13
investor education and pr... 0.15 - 0.15 0.18 0.18
kotak mahindra trustee co... - - - - 1.05
massachusetts institute o... - 2.32 2.32 2.32 2.32
orbimed asia iv mauritius... 10.88 10.88 10.88 10.88 10.88
uti-healthcare fund - - - - 1.41
uti small cap fund - 2.05 1.51 1.30 -
investor education and pr... - 0.15 - - -
quant mutual fund - quant... 2.79 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit INDIA RATINGS
Credit CARE
Credit CARE
Credit CARE
Credit FITCH
Credit CARE
Credit FITCH
Credit FITCH
Credit FITCH
TYPE AGENCY ACTION
Research Ventura
Research Ventura
Research HDFC Securities
Research Ventura
Research BP Wealth
Research HDFC Securities
Research HDFC Securities
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY23
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q2FY23
Concall Q2 FY25
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
TYPE QUARTER ACTION
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21

Company News

Marksans Pharma Stock Price Analysis and Quick Research Report. Is Marksans Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Marksans Pharma and its performance over the period of time. Marksans Pharma stock price today is Rs 259.25.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Marksans Pharma cash from the operating activity was Rs 34.052 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Marksans Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Marksans Pharma , the EPS growth was 30.0308 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Marksans Pharma has OPM of 16.399792329067 % which is a good sign for profitability.
     
  • ROE: Marksans Pharma have a average ROE of 11.4616 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Marksans Pharma is Rs 259.25. One can use valuation calculators of ticker to know if Marksans Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Marksans Pharma
X